Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets

Drugs in R and D

Volumn 6, Issue 2, 2005, Pages 91-99

  Adams, Michael P ^a   Ahdieh, Harry ^b  

^a SFBC New Drug Services   (United States)

^b ENDO PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; MU OPIATE RECEPTOR AGONIST; NALTREXONE; OXYMORPHONE;

ADULT; ANALGESIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MULTIPLE DRUG DOSE; NAUSEA AND VOMITING; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; TABLET FORMULATION; TIME; VOLUNTEER; XEROSTOMIA;

ADULT; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; OXYMORPHONE; TABLETS;

EID: 16844373756     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200506020-00004     Document Type: Article

References (13)

1. Eddy NB, Lee LEJ. The analgesic equivalence to morphine and relative side action liability of oxymorphone (4-hydroxy-dihydromorphinone). J Pharmacol Exp Ther 1959; 125 (2): 116-21
2. Sinatra RS, Hyde NH, Harrison DM. Oxymorphone revisited. Semin Anesth 1988; 7 (3): 209-15
3. Cone EJ, Darwin WD, Buchwald WF, et al. Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog. Drug Metab Dispos 1983; 11 (5): 446-50
4. Hashiguchi Y, Molina PE, Abumrad NN. Morphine-3-glucuronide: hyperglycemic and neuroendocrine potentiating effects. Brain Res 1995; 694 (1-2): 13-20
5. Ulens C, Baker L, Ratka A, et al. Morphine-6beta-glucuronide and morphine-3-glucuronide, opioid receptor agonists with different potencies. Biochem Pharmacol 2001; 62 (9): 1273-82
6. Christrup LL. Morphine metabolites. Acta Anaesthesiol Scand 1997; 41 (1 Pt 2): 116-22
7. Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 1981; 2 (2): 93-113
8. Metropolitan Life Insurance Company. New weight standards for men and women. Stat Bull Metropol Life Insur Co. 1950; 40: 1-4
9. Metropolitan Life Insurance Company. Metropolitan height and weight tables. Star Bull Metropol Life Insur Co. 1983; 64: 1-19
10. Leow KP, Smith MT, Williams B, et al. Single-dose and steadystate pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992; 52 (5): 487-95
11. Adams MP, Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy 2004; 24 (4): 468-76
12. Thirlwell MP, Sloan PA, Maroun JA, et al. Pharmacokinetics and clinical efficacy of oral morphine solution and controlled-release morphine tablets in cancer patients. Cancer 1989; 63 (11 Suppl.): 2275-83
13. Leow KP, Smith MT, Watt JA, et al. Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit 1992; 14 (6): 479-84